Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Cash & Equivalents (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Cash & Equivalents for 5 consecutive years, with $22.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 410.98% to $22.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.2 million, a 410.98% increase, with the full-year FY2025 number at $14.2 million, changed N/A from a year prior.
  • Cash & Equivalents was $22.2 million for Q4 2025 at Neuphoria Therapeutics, up from $13.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $24.0 million in Q2 2022 to a low of $4.3 million in Q4 2024.
  • A 4-year average of $14.5 million and a median of $13.9 million in 2025 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 49.26% in 2023, then skyrocketed 410.98% in 2025.
  • Neuphoria Therapeutics' Cash & Equivalents stood at $24.0 million in 2022, then crashed by 49.26% to $12.2 million in 2023, then tumbled by 64.38% to $4.3 million in 2024, then surged by 410.98% to $22.2 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Cash & Equivalents are $22.2 million (Q4 2025), $13.6 million (Q3 2025), and $14.2 million (Q2 2025).